Prior studies have shown that chronic exposure to FGF21 leads to increased adiponectin levels, which has prompted investigation of an FGF21 analogue as a potential therapeutic agent for NASH.39 This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.